(NASDAQ: ALLK) Allakos's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.19%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.88%.
Allakos's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast ALLK's revenue for 2027 to be $33,767,426,470, with the lowest ALLK revenue forecast at $33,767,426,470, and the highest ALLK revenue forecast at $33,767,426,470. On average, 1 Wall Street analysts forecast ALLK's revenue for 2028 to be $76,976,688,182, with the lowest ALLK revenue forecast at $76,976,688,182, and the highest ALLK revenue forecast at $76,976,688,182.
In 2029, ALLK is forecast to generate $49,990,890,250 in revenue, with the lowest revenue forecast at $1,983,428,675 and the highest revenue forecast at $97,998,351,826.